Armand Cognetta, Founder and CEO at General Proximity, shared a post on Linkedin:
“Proud to announce our collaboration with Daiichi Sankyo US to leverage our OmniTAC platform to identify novel Induced Proximity Medicines!”
Richard Joseph, Senior Medical Director at Daiichi Sankyo, shared this post, adding:
“Big congratulations, to Armand Cognetta!
Really exciting to see your work and the General Proximity platform recognized by Daiichi Sankyo.
I’m personally excited about the potential of proximity technology to open new frontiers in cancer drug discovery — and it’s great to see a friend leading the way.”
More posts featuring Daiichi Sankyo US.